01—Abstract
Summary
Summary of the 10-K/A filed February 25, 2004. Cited figures are marked; the original filing is the authoritative source.
Exelixis, Inc., a Delaware company headquartered in South South San Francisco, California, filed this Form 10-K/A to amend its annual report for the fiscal year ended December 31, 2003.
The amendment was filed solely to add the Amended and Restated Cancer Collaboration Agreement, dated as of December 15, 2003, with Bristol-Myers Squibb Company as Exhibit 10.41, which was inadvertently omitted from the original report filed on February 20, 2004. Except for that exhibit, the filing states that no other information in the original Form 10-K is amended. The filing reports an aggregate market value of common stock held by non-affiliates of $436,723,221,a computed as of the last business day of the second fiscal quarter, and 71,295,105 shares of common stock outstanding as of December 31, 2003.
It lists no documents incorporated by reference. The amendment's exhibit index covers the company's principal collaboration, financing, and lease arrangements, including agreements with Bristol-Myers Squibb, SmithKlineBeecham, Bayer, Pharmacia & Upjohn, Protein Design Labs, and Dow AgroSciences, as well as loan and lease agreements with Silicon Valley Bank, Comdisco, and GE Capital.
Several of these agreements carry confidential treatment for certain portions. The Form 8-K reports listed for the fourth quarter of 2003 cover a $30.0 millionb additional borrowing under the SmithKlineBeecham Loan and Security Agreement, the third-quarter 2003 financial results press release, and the departure of the company's President, Research and Development and Chief Scientific Officer.
02—Key points
Key Highlights
- Filed as Form 10-K/A to add Exhibit 10.41, the Amended and Restated Cancer Collaboration Agreement with Bristol-Myers Squibb Company dated December 15, 2003, which was omitted from the original annual report.
- Aggregate market value of common stock held by non-affiliates was $436,723,221, measured as of the last business day of the second fiscal quarter.
- 71,295,105 shares of common stock were outstanding as of December 31, 2003.
- During the fourth quarter of 2003, the company borrowed an additional $30.0 million under its Loan and Security Agreement with SmithKlineBeecham Corporation.
- The company reported the departure of its President, Research and Development and Chief Scientific Officer in an October 31, 2003 Form 8-K.
- The exhibit index lists collaboration agreements with Bristol-Myers Squibb, SmithKlineBeecham, Bayer, Pharmacia & Upjohn, Protein Design Labs, and Dow AgroSciences.
- Several collaboration agreements were filed with confidential treatment granted for certain portions.
03—Questions
Frequently Asked Questions
Why was this amended annual report filed?
The company filed this Form 10-K/A solely to add the Amended and Restated Cancer Collaboration Agreement with Bristol-Myers Squibb Company, dated as of December 15, 2003, as Exhibit 10.41. The filing states that this exhibit was inadvertently omitted from the original Form 10-K filed on February 20, 2004, and that no other information in that report is amended.
What was the company's market value and share count reported in this filing?
The filing reports an aggregate market value of $436,723,221 for common stock held by non-affiliates, computed as of the last business day of the second fiscal quarter. As of December 31, 2003, there were 71,295,105 shares of common stock outstanding.
What financing activity did the company disclose for late 2003?
The company filed a Form 8-K on December 16, 2003 announcing that it borrowed an additional $30.0 million under its Loan and Security Agreement with SmithKlineBeecham Corporation.
What management change was reported during 2003?
On October 31, 2003, the company filed a Form 8-K announcing the departure of its President, Research and Development and Chief Scientific Officer.
04—Continue